TSHA — Taysha Gene Therapies Inc
NASDAQ · Healthcare · Biotechnology
$5.70
+$0.01 (+0.18%)
Taysha Gene Therapies Inc (TSHA) is a biotechnology company listed on NASDAQ. It is led by Sean P. Nolan, based in 3000 Pegasus Park Drive, Dallas, TX, United States, 75247, with about 73 employees. Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Latest reported TSHA revenue for 2025-09-30 was $0. Net income was -$32.7M. Revenue was down 100.0% from 2025-06-30 to 2025-09-30. TSHA currently screens at market cap $640.7M.
Use this TSHA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TSHA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TSHA SEC filings page. Lician reads the product cache first so this HTML stays unique to Taysha Gene Therapies Inc even when a live quote feed is slow.
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
TSHA Key Statistics
Market Cap
$640.75M
Volume
1.69M
Previous Close
$5.97
Day Range
$5.99 – $6.27
EPS
-$0.36
Revenue
$8.33M
Net Income
-$89.30M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-46.1%
Profit Margin
-1071.6%
Employees
73
TSHA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $8.33M | $15.45M | $2.50M | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$89.30M | -$111.57M | -$166.01M | -$174.52M |
| EPS (Diluted) | -$0.36 | -$0.96 | -$3.78 | -$4.64 |
Total Assets
$160.36M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$139.04M
Operating Cash Flow
-$81.22M
Free Cash Flow
$0.00
Taysha Gene Therapies Inc Company Information
- CEO & Chairman
- Sean P. Nolan
- Headquarters
- 3000 Pegasus Park Drive, Dallas, TX, United States, 75247
- Website
- www.tayshagtx.com
- Phone
- 214 612 0000
- IPO / Founded
- 2020-09-24
- Sector
- Healthcare
- Industry
- Biotechnology